On Jul. 27, 2020, FUJIFILM Diosynth Biotechnologies (FDB) and Texas A&M announced they mass will produce vaccines as part of an agreement between the federal government and the Center for Innovation in Advanced Development and Manufacturing.

FDB was slated to use the reserved capacity at one of the FDB facilities for the COVID-19 vaccine candidate of Novavax, NVX-CoV2373.